Sermorelin is a ghrh analog with a development status of "previously fda-approved; now compounded". The Institute rates the strength of its published evidence as moderate. A truncated GHRH analog that stimulates the pituitary to release growth hormone, historically used in paediatric diagnostics.
Commercial availability of Sermorelin continues to run ahead of its regulatory status. That is the recurring structural feature of this market: demand arrives when trial data is published, and supply arrives from channels that answer to nobody in particular.
Our position on developments like this is consistent. We report what changed, we test what is being sold, and we decline to speculate about what a regulator will do next.
The Institute has independently tested 4 Sermorelin samples from 4 companies. 75% met their label claims on purity and content. Measured purity ranged from 93.2% to 98.5%, averaging 97%. 1 sample failed verification outright. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
